methyl 2-cyanomethyl-5-benzimidazolecarboxylate | 145127-12-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: methyl 2-cyanomethyl-5-benzimidazolecarboxylate
• 英文别名: methyl 2-(cyanomethyl)-3H-benzimidazole-5-carboxylate
• CAS: 145127-12-4
• 化学式: C₁₁H₉N₃O₂
• 分子量: 215.211
• InChiKey: BYGMTDWPSRRPTG-UHFFFAOYSA-N

物化性质

• 熔点：
  218-220 °C
• 沸点：
  490.1±25.0 °C(Predicted)
• 密度：
  1.351±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  78.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-cyanomethyl-5-benzimidazolecarboxylate 在 盐酸 、 溶剂黄146 作用下， 反应 3.0h， 生成 2-(cyanomethyl)-1H-benzo[d]imidazole-6-carboxylic acid
  参考文献：
  名称：

  针对BRCA1 tBRCT域的蛋白质与蛋白质相互作用的小分子抑制剂的结构指导合成和评价。

  摘要：

  BRCA1的串联BRCT结构域（tBRCT）结合靶蛋白中的含磷酸丝氨酸的基序，以传播由DNA损伤引发的细胞内信号，从而控制细胞周期停滞和DNA修复。最近，我们确定了Bractoppin，BRCA1 tBRCT域的第一个小分子抑制剂，该抑制剂选择性地中断DNA损伤引起的BRCA1介导的细胞反应。在这里，我们结合结构指导的化学精制，蛋白质诱变和细胞分析来定义负责Bractoppin活性的结构特征。Bractoppin无法结合BRCA1 tBRCT的突变形式，该突变形式带有K1702A，介导磷酸肽识别的关键残基，或邻接pSer识别位点的F1662R或L1701K。但是，M1775R突变与共有磷酸肽基序pSer-XX-Phe中的Phe残基结合，不会影响Bractoppin的结合，从而证实了与底物磷酸肽结合不同的结合方式。我们在生化分析中通过结构指导的化学加工和表征的构效关系（SAR）探索了这些结构

  DOI：

  10.1002/cmdc.201900300
• 作为产物：
  描述：

  3,4-二氨基苯甲酸甲酯 、 氰乙酰胺 以 neat (no solvent) 为溶剂， 反应 0.5h， 生成 methyl 2-cyanomethyl-5-benzimidazolecarboxylate
  参考文献：
  名称：

  Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein

  摘要：

  Human APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G, MG) is a potent restriction factor against human immunodeficiency virus type 1 (HIV-1) by inducing hypermutation of G to A in viral genome after its incorporation into virions. HIV-1 Vif (Virion Infectivity Factor) counteracts A3G by inducing ubiquitination and proteasomal degradation of MG protein. Vif-A3G axis therefore is a promising therapeutic target of HIV-1. Here we report the screening, synthesis and SAR studies of benzimidazole derivatives as potent inhibitors against HIV-1 replication via protecting MG protein. Based on the steep SAR of the benzimidazole scaffold, we identified compound 14 and 26 which provided the best potency, with IC50 values of 3.45 nM and 58.03 nM respectively in the anti-HIV-1 replication assay in H9 cells. Compound 14 and 26 also afforded protective effects on MG protein level. Both compounds have been proved to be safe in acute toxicological studies. Taken together, we suggest that these two benzimidazole derivatives can be further developed as a new category of anti-HIV-1 leads. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.03.050

文献信息

• A facile synthesis and microtubule-destabilizing properties of 4-(1H-benzo[d]imidazol-2-yl)-furazan-3-amines
  作者：Andrei I. Stepanov、Alexander A. Astrat'ev、Aleksei B. Sheremetev、Nataliya K. Lagutina、Nadezhda V. Palysaeva、Aleksei Yu. Tyurin、Nataliya S. Aleksandrova、Nataliya P. Sadchikova、Kyrill Yu. Suponitsky、Olga P. Atamanenko、Leonid D. Konyushkin、Roman V. Semenov、Sergei I. Firgang、Alex S. Kiselyov、Marina N. Semenova、Victor V. Semenov

  DOI：10.1016/j.ejmech.2015.02.051

  日期：2015.4

  4-(1H-benzo[d]imidazol-2-yl)-furazan-3-amines (BIFAs) were prepared in good yields (60–90% for each reaction step) via a novel procedure from aminofurazanyl hydroximoyl chlorides and o-diaminobenzenes. The synthetic sequence was run under mild reaction conditions, it was robust and did not require extensive purification of intermediates or final products. Furthermore, there was no need for protection of reactive moieties

  一系列的4-（1H-苯并[d]咪唑-2-基） -呋咱-3-胺（BIFAs）在良好的产率（60-90％用于每个反应步骤）制备通过一种新颖的方法，由aminofurazanyl肟基氯化物和o-二氨基苯。合成序列在温和的反应条件下运行，它很可靠，不需要大量纯化中间体或最终产物。此外，不需要保护反应性部分以允许多种BIFA衍生物的平行合成。随后对所得化合物的生物学评估表明，它们在海胆胚胎模型和培养的人类癌细胞系中具有抗增殖作用。在两种测定系统中，活性最高的化合物均显示出0.2–2μM的活性。苯并咪唑模板的未取代苯环以及呋喃环中的未取代氨基是BIFA的抗有丝分裂活性的必要先决条件。化合物57 在咪唑环的氮原子上带有2-氯苯基乙酰胺取代基的是该组中活性最高的分子。
• Synthesis and potent antimicrobial activity of some novel methyl or ethyl 1H-benzimidazole-5-carboxylates derivatives carrying amide or amidine groups
  作者：Seçkin Özden、Dilek Atabey、Sulhiye Yıldız、Hakan Göker

  DOI：10.1016/j.bmc.2004.12.025

  日期：2005.3.1

  and antifungal activities against S. aureus, methicillin resistant S. aureus (MRSA), S. faecalis, methicillin resistant S. epidermidis (MRSE), E. coli and C. albicans. The results showed that while all simple acetamides are essentially inactive, aromatic amides and amidines have potent antibacterial activities. Aromatic amidine derivatives 13 f-h exhibited the best inhibitory activity with 1.56-0.39

  合成了一系列在C-2位带有酰胺或am取代的甲基或苯基基团的苯并咪唑-5-羧酸烷基酯衍生物，并评估了其对金黄色葡萄球菌，耐甲氧西林金黄色葡萄球菌（MRSA）的抗菌和抗真菌活性，粪链球菌，耐甲氧西林的表皮葡萄球菌（MRSE），大肠杆菌和白色念珠菌。结果表明，尽管所有简单的乙酰胺基本上都没有活性，但芳族酰胺和am具有强大的抗菌活性。芳族am衍生物13 fh对MRSA和MRSE表现出最佳的抑制活性，其1.56-0.39 microg / mL MIC值。
• Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein
  作者：Ting Pan、Xin He、Bing Chen、Hui Chen、Guannan Geng、Haihua Luo、Hui Zhang、Chuan Bai

  DOI：10.1016/j.ejmech.2015.03.050

  日期：2015.5

  Human APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G, MG) is a potent restriction factor against human immunodeficiency virus type 1 (HIV-1) by inducing hypermutation of G to A in viral genome after its incorporation into virions. HIV-1 Vif (Virion Infectivity Factor) counteracts A3G by inducing ubiquitination and proteasomal degradation of MG protein. Vif-A3G axis therefore is a promising therapeutic target of HIV-1. Here we report the screening, synthesis and SAR studies of benzimidazole derivatives as potent inhibitors against HIV-1 replication via protecting MG protein. Based on the steep SAR of the benzimidazole scaffold, we identified compound 14 and 26 which provided the best potency, with IC50 values of 3.45 nM and 58.03 nM respectively in the anti-HIV-1 replication assay in H9 cells. Compound 14 and 26 also afforded protective effects on MG protein level. Both compounds have been proved to be safe in acute toxicological studies. Taken together, we suggest that these two benzimidazole derivatives can be further developed as a new category of anti-HIV-1 leads. (C) 2015 Elsevier Masson SAS. All rights reserved.
• Structure‐Guided Synthesis and Evaluation of Small‐Molecule Inhibitors Targeting Protein–Protein Interactions of BRCA1 tBRCT Domain
  作者：Vadiraj Kurdekar、Saranya Giridharan、Jasti Subbarao、Mamatha B. Nijaguna、Jayaprakash Periasamy、Sanjana Boggaram、Amol V. Shivange、Gayathri Sadasivam、Muralidhara Padigaru、Vijay Potluri、Ashok R. Venkitaraman、Kavitha Bharatham

  DOI：10.1002/cmdc.201900300

  日期：2019.9.18

  effective in abrogating BRCA1 foci formation and inhibiting G2 arrest induced by irradiation of cells. Collectively, our findings reveal structural features underlying the activity of a novel inhibitor of phosphopeptide recognition by the BRCA1 tBRCT domain, providing fresh insights to guide the development of inhibitors that target protein-protein interactions.

  BRCA1的串联BRCT结构域（tBRCT）结合靶蛋白中的含磷酸丝氨酸的基序，以传播由DNA损伤引发的细胞内信号，从而控制细胞周期停滞和DNA修复。最近，我们确定了Bractoppin，BRCA1 tBRCT域的第一个小分子抑制剂，该抑制剂选择性地中断DNA损伤引起的BRCA1介导的细胞反应。在这里，我们结合结构指导的化学精制，蛋白质诱变和细胞分析来定义负责Bractoppin活性的结构特征。Bractoppin无法结合BRCA1 tBRCT的突变形式，该突变形式带有K1702A，介导磷酸肽识别的关键残基，或邻接pSer识别位点的F1662R或L1701K。但是，M1775R突变与共有磷酸肽基序pSer-XX-Phe中的Phe残基结合，不会影响Bractoppin的结合，从而证实了与底物磷酸肽结合不同的结合方式。我们在生化分析中通过结构指导的化学加工和表征的构效关系（SAR）探索了这些结构